Clinical Trials Directory

Trials / Completed

CompletedNCT01643148

The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer

Phase 1. Collect Samples of Breast Biopsy Patients Treated at the Hospital Radiology Service Maternal Perinatal Monica Pretelini

Status
Completed
Phase
Study type
Observational
Enrollment
88 (actual)
Sponsor
Materno-Perinatal Hospital of the State of Mexico · Academic / Other
Sex
Female
Age
40 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Objective: Evaluate body mass index (BMI), leptin, Leptin/adiponectin (L/A) ratio and cancer antigen (CA) 15-3 together as reliable biomarkers for breast cancer. Patients: Consecutive patients aged between 40 - 60 years, with breast disease and informed consent. Interventions: Patients' Anthropometric and laboratorial characteristics classified by BMI in the group of cancer and patients with benign breast disease as well as biochemical tests of leptin, adiponectin,CA 15-3, hemoglobin, glucose low-density lipoprotein cholesterol (LDLC), high-density lipoprotein cholesterol (HDLC) levels were obtained as well as a blood sample to analyze CA 15-3 levels with a electrochemiluminescence immunoassay. Hypothesis: Using together leptin, L/A ratio, CA 15-3 and BMI could offer a reliable approach to detect high risk women to develop breast cancer.

Detailed description

Serum levels of leptin, adiponectin and CA 15-3, as well as anthropometric and biochemical parameters were analyzed in 88 female patients attending mammography study. Predictive values of BMI, leptin, L/A ratio and CA 15-3 were determined with 95% confidence interval (CI).

Conditions

Timeline

Start date
2011-01-01
Primary completion
2011-10-01
Completion
2012-07-01
First posted
2012-07-18
Last updated
2012-07-18

Source: ClinicalTrials.gov record NCT01643148. Inclusion in this directory is not an endorsement.